Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
Status:
Withdrawn
Trial end date:
2019-08-08
Target enrollment:
Participant gender:
Summary
Dengue fever is an acute febrile illness transmitted by mosquitoes, which affects half the
world's population. There are 96 million symptomatic infections, 500,0000 hospitalisations
and 25,000 deaths per year attributed to the disease. The economic burden is $12 billion. In
Singapore, as elsewhere, the incidence of the disease continues to increase despite
aggressive control measures. At present there are no approved medicines for treating dengue
fever. Only supportive fluid replacement therapy is used to treat vascular leakage in
patients with severe illness. Therefore there is an urgent need to find alternative
treatments. Experiments in the laboratory have shown that Celgosivir and modipafant inhibit
dengue virus and improve mouse survival. Both drugs have previously been used in humans with
good safety records, so investigators are taking this one step further to find out how well
it works in dengue patients. Investigators plan to enroll dengue patients within 48 hours of
fever onset and assign them to one of four treatment groups over five days. Together with the
support from the industry partner, 60°Pharmaceuticals PLC, the investigators will determine
the safety and effectiveness of these drugs on acute dengue patients and pave the way forward
for dengue antiviral medicines to reach patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Singapore General Hospital
Collaborators:
60 Degrees Pharmaceuticals LLC Duke-NUS Graduate Medical School